Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells

International Journal of Molecular Medicine

Volumn 21, Issue 5, 2008, Pages 637-643

  Takai, Noriyuki ^a   Ueda, Tami ^a   Nishida, Masakazu ^a   Nasu, Kaei ^a   Narahara, Hisashi ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Apoptosis; Cell cycle; Endometrial cancer; Ovarian cancer

Indexed keywords

BUFALIN; LIPOCORTIN 5; PHOSPHATIDYLSERINE; ANTINEOPLASTIC AGENT; BUFADIENOLIDE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DRUG STRUCTURE; ENDOMETRIUM CANCER; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; OVARY CANCER; PRIORITY JOURNAL; CELL CYCLE; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; ENDOMETRIUM; ENDOMETRIUM TUMOR; FEMALE; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BUFANOLIDES; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MOLECULAR STRUCTURE; OVARIAN NEOPLASMS;

EID: 46449105600     PISSN: 11073756     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijmm.21.5.637     Document Type: Article

References (23)

1. Krenn L and Kopp B: Bufadienolides from animal and plant sources. Phytochemistry 48: 1-29, 1998.
2. Hong Z, Chen K and Yeung HW: Simultaneous determination of bufadienolides in the traditional Chinese medicine preparation, Liu Shen Wan, by liquid chromatography. J Pharm Pharmacol 44: 1023-1026, 1992.
3. Song H, Guo T, Bi K, Wang H and Zhang R: Determination of resibufogenin and cinobufagin in heart-protecting musk pill by HPLC. Biomed Chromatogr 14: 130-132, 2000.
4. Morishita S, Shoji M and Oguni Y: Pharmacological actions of 'Kyusin', a drug containing toad venom: cardiotonic and arrhythmogenic effects. Am J Chin Med 20: 245-246, 1992.
5. Numazawa S, Shinoki M, Ito H, Yoshida T and Kuroiwa Y: Involvement of Na+,K+-ATPase inhibition in K562 cell differentiation induced by bufalin. J Cell Physiol 160: 113-120, 1994.
6. Jing Y, Watabe M, Hashimoto S, Nakajo S and Nakaya K: Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells. Anticancer Res 14: 1193-1198, 1994.
7. Masuda Y, Kawazoe N, Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: Bufalin induces apoptosis and influences the expression of apoptosis-related genes in human leukemia cells. Leuk Res 19: 549-556, 1995.
8. Watabe M, Ito K, Masuda Y, Nakajo S and Nakaya K: Activation of AP-1 is required for bufalin-induced apoptosis in human leukemia U937 cells. Oncogene 16: 779-787, 1998.
9. Kawazoe N, Watabe M, Masuda Y, Nakajo S and Nakaya K: Tiam1 is involved in the regulation of bufalin-induced apoptosis in human leukemia cells. Oncogene 18: 2413-2421, 1999.
10. Yeh J-Y, Huang WJ, Kan S-F and Wang PS: Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells. Prostate 54: 112-124, 2003.
11. Takai N, Desmond JC, Kumagai T, Gui D, Said JW, Whittaker S, Miyakawa I and Koeffier HP: Histone deacetylase inhibitors have a profound anti-growth activity in endometrial cancer cells. Clin Cancer Res 10: 1141-1149, 2004.
12. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I and Koeffler HP: Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 101: 2760-2770, 2004.
13. Rimon G, Bazenet CE, Philpott KL and Rubin LL: Increased Surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res 48: 563-570, 1997.
14. Chen Y, Kramer DL, Diegelman P, Vujcic S and Porter CW: Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res 61: 6437-6444, 2001.
15. Sandberg EM and Sayeski PP: Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem 279: 34547-34552, 2004.
16. Johnson DG and Walker CL: Cyclins and cell cycle check-points. Annu Rev Pharmacol Toxicol 39: 295-312, 1999.
17. Sherr CJ: G1 phase progression: cyclin on cue. Cell 79: 551-555, 1994.
18. Kyushima N, Watanabe J, Hata H, Jobo T, Kameya T and Kuramoto H: Expression of cyclin A in endometrial adenocarcinoma and its correlation with proliferative activity and clinicopathological variables. J Cancer Res Clin Oncol 128: 307-312, 2002.
19. Jing Y, Ohizumi H, Kawazoe N, Hashimoto S, Masuda Y, Nakajo S, Yoshida T, Kuroiwa Y and Nakaya K: Selective inhibitory effect of bufalin on growth of human tumor cells in vitro: association with the induction of apoptosis in leukemia HL-60 cells. Jpn J Cancer Res 85: 645-651, 1994.
20. Jones DP, McConkey DJ, Nicotera P and Orrenius S: Calcium-activated DNA fragmentation in rat liver nuclei. J Biol Chem 264: 6398-3403, 1989.
21. Trump BF and Berezesky IK: Calcium mediated cell injury and cell death. FASEB J 9: 219-228, 1995.
22. Furaya Y, Lundmo P, Short AD, Gill DL and Isaacs JY: The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin. Cancer Res 44: 3522-3529, 1984.
23. Panesar NS: Bufalin and unidentified substance(s) in traditional Chinese medicine cross-react in commercial digoxin assay. Clin Chem 38: 2155-2156, 1992.